SG11201908844YA - Vectors and compositions for treating hemoglobinopathies - Google Patents
Vectors and compositions for treating hemoglobinopathiesInfo
- Publication number
- SG11201908844YA SG11201908844YA SG11201908844YA SG11201908844YA SG 11201908844Y A SG11201908844Y A SG 11201908844YA SG 11201908844Y A SG11201908844Y A SG 11201908844YA SG 11201908844Y A SG11201908844Y A SG 11201908844YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- massachusetts
- rule
- viii
- pct
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16071—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762478375P | 2017-03-29 | 2017-03-29 | |
US201762489149P | 2017-04-24 | 2017-04-24 | |
PCT/US2018/025165 WO2018183692A1 (fr) | 2017-03-29 | 2018-03-29 | Vecteurs et compositions pour le traitement d'hémoglobinopathies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908844YA true SG11201908844YA (en) | 2019-10-30 |
Family
ID=63677097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201908844Y SG11201908844YA (en) | 2017-03-29 | 2018-03-29 | Vectors and compositions for treating hemoglobinopathies |
Country Status (10)
Country | Link |
---|---|
US (1) | US20220259594A1 (fr) |
EP (1) | EP3600448A4 (fr) |
JP (2) | JP7228523B2 (fr) |
CN (1) | CN110582305A (fr) |
AU (1) | AU2018243293A1 (fr) |
BR (1) | BR112019020322A2 (fr) |
CA (1) | CA3057862A1 (fr) |
IL (1) | IL269551A (fr) |
SG (1) | SG11201908844YA (fr) |
WO (1) | WO2018183692A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114450412A (zh) * | 2019-06-05 | 2022-05-06 | 奥查德疗法(欧洲)有限公司 | 用于修饰真核细胞的组合物和方法 |
WO2021067389A1 (fr) * | 2019-09-30 | 2021-04-08 | Bioverativ Therapeutics Inc. | Formulations de vecteur lentiviral |
CN117384967A (zh) * | 2020-04-24 | 2024-01-12 | 康霖生物科技(杭州)有限公司 | 一种核酸构建体 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112014007782B1 (pt) * | 2011-09-30 | 2021-06-01 | Bluebird Bio, Inc. | Método para aumentar a eficiência de transdução lentiviral de células progenitoras ou células-tronco hematopoiéticas cd34+, bem como usos terapêuticos de composição compreendendo as ditas células e de pge2, 16,16-dimetil pge2, ou seu análogo |
WO2014093965A1 (fr) * | 2012-12-14 | 2014-06-19 | Case Western Reserve University | Elément activateur d'encapsidation d'arn génomique |
EP3998278A1 (fr) * | 2014-04-25 | 2022-05-18 | 2seventy bio, Inc. | Récepteurs d'antigènes chimériques de promoteur mnd |
EP3598984B1 (fr) * | 2014-04-25 | 2024-04-10 | The Children's Medical Center Corporation | Compositions et procédés pour le traitement d'hémoglobinopathies |
EP3134434A4 (fr) * | 2014-04-25 | 2017-10-25 | Bluebird Bio, Inc. | Récepteurs d'antigènes chimères kappa/lambda |
CN114480393A (zh) * | 2014-09-04 | 2022-05-13 | 纪念斯隆-凯特琳癌症中心 | 用于治疗血红蛋白病的球蛋白基因治疗 |
PT3628687T (pt) * | 2014-12-12 | 2021-10-20 | Bluebird Bio Inc | Recetores do antigénio quimérico bcma |
ES2764457T3 (es) * | 2015-03-31 | 2020-06-03 | Glycotope Gmbh | Vectores de expresión eucariotas que incluyen elementos reglamentarios de los grupos de genes de globina |
EP3344295B1 (fr) * | 2015-08-31 | 2022-02-23 | Helixmith Co., Ltd. | Récepteurs d'antigène chimère tn anti-sialyle |
-
2018
- 2018-03-29 CA CA3057862A patent/CA3057862A1/fr active Pending
- 2018-03-29 SG SG11201908844Y patent/SG11201908844YA/en unknown
- 2018-03-29 WO PCT/US2018/025165 patent/WO2018183692A1/fr unknown
- 2018-03-29 AU AU2018243293A patent/AU2018243293A1/en active Pending
- 2018-03-29 BR BR112019020322A patent/BR112019020322A2/pt unknown
- 2018-03-29 CN CN201880027694.4A patent/CN110582305A/zh active Pending
- 2018-03-29 EP EP18775163.1A patent/EP3600448A4/fr active Pending
- 2018-03-29 JP JP2019553350A patent/JP7228523B2/ja active Active
-
2019
- 2019-09-23 IL IL26955119A patent/IL269551A/en unknown
-
2022
- 2022-01-28 US US17/587,999 patent/US20220259594A1/en active Pending
-
2023
- 2023-01-18 JP JP2023005869A patent/JP2023033551A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CN110582305A (zh) | 2019-12-17 |
EP3600448A4 (fr) | 2021-01-27 |
BR112019020322A2 (pt) | 2020-04-28 |
WO2018183692A8 (fr) | 2019-05-02 |
AU2018243293A1 (en) | 2019-10-31 |
US20220259594A1 (en) | 2022-08-18 |
JP2020511991A (ja) | 2020-04-23 |
CA3057862A1 (fr) | 2018-10-04 |
JP2023033551A (ja) | 2023-03-10 |
WO2018183692A1 (fr) | 2018-10-04 |
IL269551A (en) | 2019-11-28 |
JP7228523B2 (ja) | 2023-02-24 |
EP3600448A1 (fr) | 2020-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
SG11201906763RA (en) | Pyrrolo [1,2-b] pyridazine derivatives | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201909777YA (en) | Modulatory polynucleotides | |
SG11201901066UA (en) | Novel alkaline stable immunoglobulin-binding proteins | |
SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
SG11201907653QA (en) | Compositions and methods for enhanced gene expression | |
SG11201909868YA (en) | Compositions and methods of treating huntington's disease | |
SG11201811603WA (en) | Novel adeno-associated virus capsid proteins | |
SG11201808812RA (en) | Novel aav8 mutant capsids and compositions containing same | |
SG11201907846VA (en) | Therapeutic rna | |
SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201908575SA (en) | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy | |
SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
SG11201909203WA (en) | Tissue selective transgene expression | |
SG11201807912SA (en) | Vaccine against rsv | |
SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
SG11201805579SA (en) | Recombinant igg fc multimers | |
SG11201408054RA (en) | Pegylated oxm variants |